A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Principal Investigator
John SwistonOverview
Study Start/End
Sep 16, 2019 to Dec 31, 2021Locations
Diamond Health Care CentreName/Title
Mami Okada, Research CoordinatorPhone
604-875-4111 ext.69831Email Address
mami.okada@vch.caPurpose of Study
The purpose of this study is to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.